You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. CNT-Vectored Delivery of mRNA for HIV-Vaccines

    SBC: Luna Innovations Incorporated            Topic: NIAID

    Developing safe and effective preventives for HIV remains the hope for controlling the global AIDS epidemicRecentlymRNA vaccines have emerged as a promising alternative to conventional vaccine approaches because of their high potencycapacity for rapid developmentpotential for low cost manufactureTo datethere is no effective mRNA protective vaccine for HIVand the need for one is vastDespite the adv ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. FAST-CMV: A Point-of-Care Cytomegalovirus Serodiagnostic and Avidity Assy

    SBC: Luna Innovations Incorporated            Topic: NIAID

    Congenital cytomegalovirusCMVinfection is the leading cause of permanent disabilitiescognitive impairmentand sensorineural hearing loss to newbornsMaternal infections that occur during pregnancy and symptomatic congenital CMV infections have been correlated with the most severe complicationsClinical trials are currently evaluating safety and immunogenicity of diverse vaccine candidates driven by t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: Zymeron Corporation            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Antimicrobial and Biocompatible Endotracheal Tubes

    SBC: Wynnvision LLC            Topic: NHLBI

    Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following endotracheal intubation and accounts for half of all cases of hospital-acquired pneumonia. CDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infection. Responding to this unmet need, WynnVision LLC, ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Software for predicting a drug's potential to cause acute kidney injury

    SBC: DILIsym Services, Inc.            Topic: 400

    The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: Glycan Therapeutics Corporation            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Patient/Resident Mobility Tracker (PREEMPT)

    SBC: BARRON ASSOCIATES, INC.            Topic: 600

    Project Summary/Abstract Problem Hospitalization and prolonged immobilization often lead to the functional decline of vulnerable older persons. Bed rest and inactivity accelerate the functional changes that are part of normal aging; the link between inactivity and adverse outcomes is increasingly appreciated by medical professionals, and the mobilization of patients is a critical aspect of patient ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. PIC1 pre-clinical formulation and optimization as a novel anti-inflammatory pharmacological agent

    SBC: ReAlta Life Sciences, Inc.            Topic: NIAID

    The hypothesis for the proposed project is that inhibition of the classical complement pathway with Peptide Inhibitor of Complement C1 (PIC1) will be neuroprotective in a rat model of neonatal hypoxic-ischemic encephalopathy (HIE). HIE is an ischemia-reperfusion injury of the brain that occurs around the time of birth, with up to 60% mortality and 25% of survivors left with a significant disabilit ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government